FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115904013> ?p ?o ?g. }

• W2115904013 endingPage "8" @default.
• W2115904013 startingPage "4" @default.
• W2115904013 abstract "The adjuvant treatment of colon cancer is now accepted as an effective therapy following surgical resection of the primary tumor in patients at high risk for relapse. Results of studies conducted in the last 10 years have confirmed the benefits of using various 5-fluorouracil (5-FU)-based chemotherapy regimens to decrease recurrence rates and improve patient survival. The North Central Cancer Treatment Group-Mayo Clinic studies have made a significant contribution to establishing the role of adjuvant therapy in colon cancer. Our first study to suggest the effectiveness of adjuvant chemotherapy in patients with stage III disease was reported in 1989. The study used a combination of 5-FU and the anthelminthic agent levamisole, tested because of its ability to positively modulate the human cellular immune system. The results of this study were confirmed by a larger Intergroup study (0035) showing significant decreases in relapse and death rates in stage III colon cancer patients treated with 5-FU plus levamisole compared with surgery alone. Clinical trials conducted throughout the 1990s tested various 5-FU based regimens against the standard 5-FU and levamisole combination. From these trials, the combination of 5-FU plus leucovorin emerged as the standard surgical adjuvant treatment of colon cancer. The efficacy of treatment with this regimen for 6 months was similar to that of a 1-year 5-FU plus levamisole regimen. These findings led to the design of trials in which 5-FU was combined with both leucovorin and levamisoie. No differences in efficacy were found in any of the various combinations tested. Current clinical trials are investigating the use of newer agents such as CPT-II in the adjuvant setting. The results of these trials may further improve the efficacy of adjuvant therapy in patients with high-risk colon cancer." @default.
• W2115904013 created "2016-06-24" @default.
• W2115904013 creator A5062302578 @default.
• W2115904013 date "2001-02-01" @default.
• W2115904013 modified "2023-10-15" @default.
• W2115904013 title "North Central Cancer Treatment Group-Mayo Clinic trials in colon cancer" @default.
• W2115904013 cites W1795564265 @default.
• W2115904013 cites W1840481440 @default.
• W2115904013 cites W1958418663 @default.
• W2115904013 cites W1962875322 @default.
• W2115904013 cites W2006824814 @default.
• W2115904013 cites W2038925947 @default.
• W2115904013 cites W2051318720 @default.
• W2115904013 cites W2077084881 @default.
• W2115904013 cites W2096122707 @default.
• W2115904013 cites W2150985317 @default.
• W2115904013 cites W2159848047 @default.
• W2115904013 cites W2255487108 @default.
• W2115904013 cites W2313857605 @default.
• W2115904013 cites W562473934 @default.
• W2115904013 doi "https://doi.org/10.1016/s0093-7754(01)90244-1" @default.
• W2115904013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11273589" @default.
• W2115904013 hasPublicationYear "2001" @default.
• W2115904013 type Work @default.
• W2115904013 sameAs 2115904013 @default.
• W2115904013 citedByCount "9" @default.
• W2115904013 countsByYear W21159040132013 @default.
• W2115904013 crossrefType "journal-article" @default.
• W2115904013 hasAuthorship W2115904013A5062302578 @default.
• W2115904013 hasConcept C121608353 @default.
• W2115904013 hasConcept C126322002 @default.
• W2115904013 hasConcept C141071460 @default.
• W2115904013 hasConcept C143998085 @default.
• W2115904013 hasConcept C2776694085 @default.
• W2115904013 hasConcept C2777863537 @default.
• W2115904013 hasConcept C2777982462 @default.
• W2115904013 hasConcept C2781325985 @default.
• W2115904013 hasConcept C2781413609 @default.
• W2115904013 hasConcept C526805850 @default.
• W2115904013 hasConcept C535046627 @default.
• W2115904013 hasConcept C71924100 @default.
• W2115904013 hasConcept C90924648 @default.
• W2115904013 hasConceptScore W2115904013C121608353 @default.
• W2115904013 hasConceptScore W2115904013C126322002 @default.
• W2115904013 hasConceptScore W2115904013C141071460 @default.
• W2115904013 hasConceptScore W2115904013C143998085 @default.
• W2115904013 hasConceptScore W2115904013C2776694085 @default.
• W2115904013 hasConceptScore W2115904013C2777863537 @default.
• W2115904013 hasConceptScore W2115904013C2777982462 @default.
• W2115904013 hasConceptScore W2115904013C2781325985 @default.
• W2115904013 hasConceptScore W2115904013C2781413609 @default.
• W2115904013 hasConceptScore W2115904013C526805850 @default.
• W2115904013 hasConceptScore W2115904013C535046627 @default.
• W2115904013 hasConceptScore W2115904013C71924100 @default.
• W2115904013 hasConceptScore W2115904013C90924648 @default.
• W2115904013 hasLocation W21159040131 @default.
• W2115904013 hasOpenAccess W2115904013 @default.
• W2115904013 hasPrimaryLocation W21159040131 @default.
• W2115904013 hasRelatedWork W1987635368 @default.
• W2115904013 hasRelatedWork W2029644829 @default.
• W2115904013 hasRelatedWork W2040161133 @default.
• W2115904013 hasRelatedWork W2044069822 @default.
• W2115904013 hasRelatedWork W2090349639 @default.
• W2115904013 hasRelatedWork W2115904013 @default.
• W2115904013 hasRelatedWork W2415836722 @default.
• W2115904013 hasRelatedWork W2652729657 @default.
• W2115904013 hasRelatedWork W2897782746 @default.
• W2115904013 hasRelatedWork W6779540 @default.
• W2115904013 hasVolume "28" @default.
• W2115904013 isParatext "false" @default.
• W2115904013 isRetracted "false" @default.
• W2115904013 magId "2115904013" @default.
• W2115904013 workType "article" @default.